MHLW Advisory Committee to Review Reversal Agent for Prazaxa on Sept. 7

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) will discuss on September 7 whether to recommend approval for Nippon Boehringer Ingelheim’s idarucizumab, a specific reversal agent for its anticoagulant Prazaxa (dabigatran). The Pharmaceutical Affairs and...read more